Latest news and press releases about Viatris Inc. (VTRS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).
Price
| Price | $17.60 |
| Market Cap | $20.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -70.63 |
| Dividend Yield | 2.73% |
Profitability
| Return on Equity | -23.89% |
| Return on Invested Capital | -7.95% |
| Return on Assets | -9.45% |
| Gross Margin | 34.83% |
| Operating Margin | -0.59% |
| Net Margin | -2.79% |
Related companies: BAX · BBIO · ELAN · EXAS · IONS · MRNA · NBIX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of VTRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks